Pitcairn CO Aurinia Pharmaceuticals Inc. Transaction History

Pitcairn CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$8.95 - $12.8 $7,159 - $10,240	800 Added 4.35%	19,205 $193,000
Q1 2022 May 12, 2022	SELL	$10.05 - $22.48 $28,622 - $64,023	-2,848 Reduced 13.4%	18,405 $228,000
Q4 2021 Feb 14, 2022	SELL	$17.78 - $33.08 $13,192 - $24,545	-742 Reduced 3.37%	21,253 $486,000
Q3 2021 Nov 10, 2021	SELL	$10.93 - $23.55 $103,922 - $223,913	-9,508 Reduced 30.18%	21,995 $487,000
Q2 2021 Aug 11, 2021	BUY	$10.0 - $14.52 $76,760 - $111,455	7,676 Added 32.22%	31,503 $408,000
Q1 2021 May 10, 2021	BUY	$12.3 - $18.73 $293,072 - $446,279	23,827 New	23,827 $309,000

209

58.7M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.15B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Pitcairn CO, based on Form 13F filings with the SEC.

Stay updated on Pitcairn CO with notifications on news.